A once-monthly investigational therapy for metabolic dysfunction-associated steatohepatitis (MASH), called efimosfermin, has earned two new regulatory designations — one in the U.S. and the other…

Due to limited access to genetic testing, a young girl with Alagille syndrome in Indonesia was misdiagnosed in infancy with biliary atresia —…

The U.S. Food and Drug Administration (FDA) has accepted and placed under priority review an application seeking approval of bepirovirsen, GlaxoSmithKline (GSK)’s investigational therapy,…